Executive interview – VolitionRx Discusses FY18 Results and Provides a Business Update

Executive interview – VolitionRx Discusses FY18 Results and Provides a Business Update

In this interview, Cameron Reynolds, President and Chief Executive Office of Volition, discusses the Company’s financial results and provides a business update for the full fiscal year ended December 31, 2018. The Company made significant progress on building out it’s Nu.QTM platform and reported positive initial data from its first product grade assays. The team aims to further strengthen their product pipeline beyond colorectal cancer to include several cancers and diseases, along with advancing the Nu.Q Capture and Nu.Q Vet products to help drive early revenue.


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free